Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 33
Filtrar
1.
Surg Endosc ; 37(10): 7520-7529, 2023 10.
Artigo em Inglês | MEDLINE | ID: mdl-37418148

RESUMO

BACKGROUND: Delayed bleeding is the most frequent complication after endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR) of large colon polyps. Today, prophylactic clipping with through-the-scope clips (TTSCs) is commonly used to reduce the risk of bleeding. However, the over-the-scope clip (OTSC) system might be superior to TTSCs in achieving hemostasis. This study aims to evaluate the efficacy and safety of prophylactic clipping using the OTSC system after ESD or EMR of large colon polyps. METHODS: This is a retrospective analysis of a prospective collected database from 2009 until 2021 of three endoscopic centers. Patients with large (≥ 20 mm) colon polyps were enrolled. All polyps were removed by either ESD or EMR. After the resection, OTSCs were prophylactically applied on parts of the mucosal defect with a high risk of delayed bleeding or/and perforation. The main outcome measurement was delayed bleeding. RESULTS: A total of 75 patients underwent ESD (67%, 50/75) or EMR (33%, 25/75) in the colorectum. The mean resected specimen diameter was 57 mm ± 24.1 (range 22-98 mm). The mean number of OTSCs placed on the mucosal defect was 2 (range 1-5). None of the mucosal defects were completely closed. Intraprocedural bleeding occurred in 5.3% (ESD 2.0% vs. EMR 12.0%; P = 0.105), and intraprocedural perforation occurred in 6.7% (ESD 8% vs. EMR 4%; P = 0.659) of the patients. Hemostasis was achieved in 100% of cases of intraprocedural bleeding, whereas two patients required surgical conversion due to intraprocedural perforation. Among the remaining 73 patients who received prosphylactic clipping, delayed bleeding occurred in 1.4% (ESD 0% vs. EMR 4.2%; P = 0.329), and delayed perforation occurred in 0%. CONCLUSIONS: The prophylactic partial closure of large post-ESD/EMR mucosal defects using OTSCs could serve as an effective strategy to reduce the risk of delayed bleeding and perforation. The prophylactic partial closure of large complex post-ESD/EMR mucosal defects using OTSCs could serve as an effective strategy to reduce the risk of delayed bleeding and perforation.


Assuntos
Pólipos do Colo , Ressecção Endoscópica de Mucosa , Humanos , Ressecção Endoscópica de Mucosa/efeitos adversos , Estudos Retrospectivos , Estudos Prospectivos , Resultado do Tratamento , Pólipos do Colo/cirurgia , Colo
2.
Dig Dis ; 30(1): 80-2, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22572691

RESUMO

Treatment of diverticulitis comprises at least two options: conservative or surgical management. There is a recent trend to limit surgical treatment of acute diverticulitis and to favor conservative management. This review addresses general aspects of conservative patient care with special focus on the treatment of patients with a first attack of diverticulitis. The presentation does not include a discussion of specific drugs which is given in other sections of this issue.


Assuntos
Doença Diverticular do Colo/terapia , Antibacterianos/uso terapêutico , Dieta , Doença Diverticular do Colo/complicações , Doença Diverticular do Colo/tratamento farmacológico , Doença Diverticular do Colo/cirurgia , Humanos , Pacientes Internados , Pacientes Ambulatoriais , Dor/etiologia
3.
Z Gastroenterol ; 50(3): 316-22, 2012 Mar.
Artigo em Alemão | MEDLINE | ID: mdl-22383287

RESUMO

Toxic megacolon is a rare and life-threatening complication of severe colitis, defined as a dilatation of the colon > 6 cm in the absence of distal obstruction in combination with signs of systemic toxicity (major criteria: fever, tachycardia, leukocytosis, anaemia). Various triggers are known and the most common causes are underlying ulcerative colitis and Clostridium difficile. Diagnosis can easily be made by clinical examination, routine laboratory parameters and a plain X-ray of the abdomen. Much more difficult is to decide between non-surgical treatment including intensive care treatment or surgery (mostly subtotal colectomy with terminal ileostomy). Non-surgical therapy includes balancing of electrolytes and fluid volumes, broad-spectrum antibiotics including metronidazole, positioning of patients and probably careful intermittent decompression. In case of ulcerative colitis immunosuppression should be started with corticosteroids and potentially with calcineurin inhibitors. In pseudomembranous colitis vancomycin should be given orally and metronidazole should be given intravenously. As far as possible the patient should be treated in a centre with experience in the field.


Assuntos
Antibacterianos/uso terapêutico , Colite/diagnóstico , Colite/terapia , Hidratação/tendências , Imunossupressores/uso terapêutico , Megacolo Tóxico/diagnóstico , Megacolo Tóxico/terapia , Colite/complicações , Cuidados Críticos/métodos , Humanos , Megacolo Tóxico/etiologia , Resultado do Tratamento
4.
Eur J Med Res ; 16(9): 411-4, 2011 Sep 12.
Artigo em Inglês | MEDLINE | ID: mdl-22024442

RESUMO

OBJECTIVE: Fibrosing colonopathy (FC) is a rare entity associated with cystic fibrosis (CF). Until now, patients with stricturing FC have usually been treated surgically. In this instance, we aimed at avoiding surgery by applying a new conservative approach. - METHODS: Case report on an adult with CF who developed persistent abdominal pain due to a non-passable stricture in the right transverse colon. Histology confirmed fibrosing colonopathy. - RESULTS: Initially we treated the patient with prednisolone pulse therapy and additive antibiotic therapy. For maintenance therapy we administered budesonide. The patient underwent clinical, laboratory and endoscopic follow-up over a three-year period. The stricture healed and was easy to pass. A relapse in the cecum at the ileocecal valve again improved under steroid and antibiotic therapy. - CONCLUSIONS: We present a novel therapeutic approach for advanced stricturing FC in an adult patient which successfully avoided surgery (right hemicolectomy) over a three year follow up.


Assuntos
Colo/patologia , Doenças do Colo/tratamento farmacológico , Doenças do Colo/etiologia , Fibrose Cística/complicações , Fibrose/tratamento farmacológico , Fibrose/etiologia , Adulto , Antibacterianos/uso terapêutico , Seguimentos , Humanos , Masculino , Fatores de Tempo , Resultado do Tratamento
5.
Eur J Clin Invest ; 39(6): 481-8, 2009 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-19397691

RESUMO

BACKGROUND: Keratins are intermediate filament proteins of epithelial cells with pivotal functions for cell integrity. They comprise keratins 18 [K18] and 8 [K8] in hepatocytes. Keratins are of major importance for an intact cellular microarchitecture and have protective functions in human liver diseases. In mice, K8 has been demonstrated to protect against Fas-antibody-induced liver failure by direct interaction with apoptotic regulators, while the role of K18 remains unresolved. MATERIALS AND METHODS: We analysed effects of K18 deficiency on Fas-induced liver failure in mice. We determined survival and analysed induction of apoptosis after injection of the agonistic Fas antibody Jo2 into K18(-/-) and wild-type control mice by TUNEL assay and fluorometrically analysed caspase-3, -8 and -9 activities 1, 2 and 3 h after Jo2 injection. RESULTS: In K18(-/-) mice, survival of Fas-antibody treated mice was significantly shorter than that of wild-type controls (P = 0.02). However, shortened survival of K18(-/-) mice was caused by increased hepatic damage but was not correlated to enhanced induction of apoptotic pathways, as neither numbers of TUNEL positive apoptotic cells nor activities of caspases-3, -8 and -9 differed between K18(-/-) and K18(+/+) mice at any point of time. CONCLUSION: K18(-/-) mice are significantly more susceptible to Fas-antibody-induced liver failure. The cytoprotective effect of K18 is not explained by a differential activation of caspases-3, -8 and -9, suggesting that K18 does not directly interfere with apoptotic regulators. Importantly, however, K18 exerts significant protective functions by other mechanisms.


Assuntos
Anticorpos/metabolismo , Proteínas Reguladoras de Apoptose/metabolismo , Caspases/metabolismo , Queratina-18/metabolismo , Falência Hepática/metabolismo , Animais , Anticorpos/genética , Proteínas Reguladoras de Apoptose/genética , Caspases/genética , Células Cultivadas , Queratina-18/genética , Queratina-8 , Falência Hepática/genética , Camundongos , Transporte Proteico/genética , Transdução de Sinais/genética
7.
Endoscopy ; 40(8): 656-63, 2008 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-18680077

RESUMO

BACKGROUND AND STUDY AIMS: Ileocolonoscopy including biopsies is the first-line investigation in the diagnosis, management, and monitoring of inflammatory bowel disease (IBD). However, data on its safety, feasibility, and tolerability, especially in patients with extensive or severe inflammation, are rare. The aim of this study was to assess prospectively the risks of ileocolonoscopy in relation to various disease patterns and to compare possible burdens of the procedure in the endoscopist's and the patient's perception. PATIENTS AND METHODS: We prospectively analyzed a total of 558 consecutive patients, 482 with a confirmed diagnosis of IBD and 76 with suspected IBD. Data were recorded regarding the indication for ileocolonoscopy, sedation, procedure time, completion rate, feasibility of the procedure, patient tolerance, and procedure-related and postprocedure complications. Endoscopic data included the region involved, the nature of the involvement, activity of the disease, and number of biopsies. RESULTS: In 558 endoscopic procedures performed by 14 gastroenterologists no procedure-related deaths occurred. Major complications, defined as bleeding (n = 1) or perforation (n = 3), occurred in 4/558 patients (0.7 %). Minor complications, which included intense flatulence, tachycardia, allergic reaction to a sedation drug, and autonomic symptoms such as nausea, vomiting, and intense perspiration, occurred in 22/558 patients (3.9 %). There was no relationship between the complication rate and the activity of the disease. Mean procedure time was 21.0 minutes and the completion rate, defined by intubation of the terminal ileum, was 94.6 %. We documented a high tolerability independent of the severity of the disease. CONCLUSIONS: Ileocolonoscopy is a safe and feasible procedure in patients with IBD and is well tolerated by patients when carried out by well-trained endoscopists.


Assuntos
Colonoscopia/métodos , Doenças Inflamatórias Intestinais/diagnóstico , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Biópsia , Distribuição de Qui-Quadrado , Colonoscopia/efeitos adversos , Diagnóstico Diferencial , Estudos de Viabilidade , Feminino , Humanos , Íleo/patologia , Doenças Inflamatórias Intestinais/patologia , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Medição de Risco , Segurança , Estatísticas não Paramétricas
8.
J Immunol Methods ; 224(1-2): 61-7, 1999 Apr 22.
Artigo em Inglês | MEDLINE | ID: mdl-10357207

RESUMO

Chemokines are a group of inducible, locally acting proinflammatory cytokines which have been implicated in the pathogenesis of a variety of diseases. Important members of the group include monocyte chemoattractant protein (MCP)-1, -2, -3, macrophage inhibitory protein (MIP)-1alpha, -1beta and RANTES (regulated upon activation, normal T expressed and secreted). To facilitate further investigation of the human chemokines, we have constructed a novel multispecific competitor fragment containing primer binding sites for the CC-chemokines MCP-1, MCP-2, MCP-3, MIP-1alpha, MIP-1beta and RANTES, the CXC-chemokines MIP-2alpha, MIP-2beta as well as for the housekeeping gene beta-actin. Using this competitor fragment we can demonstrate reliable semiquantitation of reverse transcribed chemokine mRNAs. The assay should be useful for further studies, in particular for the semiquantitation of chemokine mRNA species from small cell or tissue specimens.


Assuntos
Quimiocinas/genética , RNA Mensageiro/análise , Actinas/genética , Sítios de Ligação , Ligação Competitiva , Primers do DNA , Amplificação de Genes , Humanos , Cinética , Lipopolissacarídeos/farmacologia , Reação em Cadeia da Polimerase , Transcrição Gênica , Células U937
9.
J Immunol Methods ; 241(1-2): 109-19, 2000 Jul 31.
Artigo em Inglês | MEDLINE | ID: mdl-10915853

RESUMO

A reverse transcription/real-time polymerase chain reaction (PCR) assay was established to semi-quantify the mRNA levels of the human C-C chemokines RANTES, MIP-1beta and MCP-1 relative to the housekeeping gene beta-actin. The assay showed a high sensitivity (below 60 cDNA molecules/10 microl reaction) and dynamic range (8 log units); both within-assay and inter-assay variability were below 0.06 log units and the accuracy was +/-0.06 log units for all four chemokines. Moreover, it is demonstrated that a multi-specific DNA fragment, which had previously been constructed for competitive PCR, can be used as a reliable external standard. This allows a direct semi-quantitative comparison of different chemokine mRNA levels and is a convenient alternative to the use of different sets of homologous external standards. The method was successfully applied to the semi-quantification of chemokines in human liver specimens and should be useful in further studies on steady state mRNA levels of C-C chemokines from low cell numbers or small tissue specimens.


Assuntos
Quimiocinas CC/isolamento & purificação , RNA Mensageiro/isolamento & purificação , Reação em Cadeia da Polimerase Via Transcriptase Reversa/métodos , Quimiocina CCL2/genética , Quimiocina CCL4 , Quimiocina CCL5/genética , Quimiocinas CC/genética , Hepatite C Crônica/genética , Hepatite C Crônica/imunologia , Humanos , Fígado/química , Cirrose Hepática Biliar/genética , Cirrose Hepática Biliar/imunologia , Proteínas Inflamatórias de Macrófagos/genética , Reação em Cadeia da Polimerase Via Transcriptase Reversa/normas
10.
J Neuroimmunol ; 49(1-2): 97-108, 1994 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-8294565

RESUMO

Synthesis of anti-ganglioside GM1 antibodies of the IgM class by peripheral blood mononuclear cells (PBMNC) from patients with immune-mediated neuropathies and motor neuron diseases and from normal controls was stimulated by Pokeweed mitogen (PWM) in vitro. In patients with acute Guillain-Barré syndrome or multifocal motor neuropathy and high serum titers of IgM anti-ganglioside GM1 antibodies this culture response was greatly enhanced as compared to controls and already detectable in unstimulated cultures. Limiting dilution analysis demonstrated high frequencies of GM1-specific B cells in these patients. Anti-ganglioside GM1 antibodies of the IgG and IgA class were only produced by PBMNC from patients with Guillain-Barré syndrome corresponding to serum titers. In cultures taken at intervals over 6 months in vitro B cell activity for IgM, IgG and IgA anti-ganglioside GM1 antibodies in two Guillain-Barré syndrome patients declined accompanied by clinical improvement and falling serum titers. We conclude that GM1-specific PWM-responsive B cells pre-exist in peripheral blood and respond to T cell-dependent stimulation in Guillain-Barré syndrome and multifocal motor neuropathy.


Assuntos
Linfócitos B/imunologia , Gangliosídeo G(M1)/imunologia , Doença dos Neurônios Motores/imunologia , Polirradiculoneuropatia/imunologia , Linfócitos T/fisiologia , Adulto , Idoso , Células Cultivadas , Feminino , Humanos , Imunoglobulina M/biossíntese , Imunoglobulina M/sangue , Masculino , Pessoa de Meia-Idade
11.
Biomed Pharmacother ; 53(5-6): 242-54, 1999 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-10424246

RESUMO

Type I interferons, which are mostly alpha-interferons (either as single agents or in combination with antiviral drugs), are currently the standard therapy for chronic viral hepatitis B, B/D, and C. Side-effects are not uncommon and include exacerbation of pre-existing autoimmune disorders or the de novo induction of autoimmunity. These adverse effects are attributed to the immunomodulatory properties of type I interferons, and should be distinguished from autoimmunity associated with chronic viral hepatitis in which interferon treatment may indeed be beneficial. The major autoimmune side-effects of interferon therapy for chronic viral hepatitis are thyroid or liver disease. Therefore, screening for thyroid antibodies and auto-antibodies indicative of autoimmune hepatitis both before, during, and after interferon therapy is strongly recommended. The presence of high concentrations of thyroid auto-antibodies or antibodies associated with autoimmune hepatitis can be contraindicative to interferon therapy. However, treatment is not contraindicated in viral hepatitis (in particular chronic hepatitis C) associated with autoimmune phenomena--including low-titer thyroid antibodies or other non-organ specific auto-antibodies. If interferon-induced autoimmunity occurs, the necessity of therapy has to be balanced carefully against the risks of autoimmune disease. Further research is needed to identify the factors which determine susceptibility to interferon-associated autoimmunity in individual patients.


Assuntos
Autoimunidade/fisiologia , Hepatite Viral Humana/complicações , Interferon Tipo I/efeitos adversos , Doença Crônica , Hepatite Viral Humana/terapia , Humanos , Interferon Tipo I/uso terapêutico , Proteínas Recombinantes
12.
Eur J Med Res ; 5(5): 199-202, 2000 May 23.
Artigo em Inglês | MEDLINE | ID: mdl-10806121

RESUMO

BACKGROUND/AIM: The admission to intensive care is controversially discussed in patients with HIV infection, since life expectancy is limited. Therefore, we analyzed indications, outcomes and follow up of all patients with confirmed HIV-infection and Aids defining symptoms who had been admitted to the intensive care unit (ICU) of our department between 1985-1996. RESULTS: 49 patients were admitted to the ICU, 42 of them with CDC stage C of HIV infection before admission. The leading indications were pneumonia (n = 15; PCP: 10, bacterial: 5), acute bleedings (n = 14), acute neurological diseases (n = 6), and gastrointestinal perforation (n = 5). Overall mortality was 39% (19/49) with a higher mortality seen in patients with respiratory disorders (53%) compared to non-respiratory disorders (22%, n.s.). The only significant predictor of mortality was the serum creatinine (p = 0.001), while differences in the APACHE II score between survivors and non-survivors did not reach statistical significance (22 +/- 7, 16 +/- 5; p = 0.14). During follow up no difference was seen in the life expectancy of HIV-infected survivors of intensive care as compared to those patients with AIDS who had never been admitted to ICU (8.4 months versus 9 months). DISCUSSION: The need for intensive care in HIV infected patients does not accelerate the progression of HIV infection to death, if the complications requiring ICU intervention can be managed successfully. Respiratory infections and impaired renal function are risk factors for a fatal outcome. Thus, HIV infected patients benefit from intensive care therapy.


Assuntos
Cuidados Críticos , Infecções por HIV/terapia , Avaliação de Processos e Resultados em Cuidados de Saúde , Adulto , Feminino , Seguimentos , Infecções por HIV/mortalidade , Humanos , Masculino , Pessoa de Meia-Idade
13.
Chirurg ; 85(4): 299-303, 2014 Apr.
Artigo em Alemão | MEDLINE | ID: mdl-24610006

RESUMO

Diverticulosis and diverticular disease are a common problem in daily practice and one third of the patients with diverticulosis develop symptoms. Patients with uncomplicated diverticulitis are very often treated with antibiotics. There is growing evidence that antibiotics are not necessary in uncomplicated cases. One problem is the different classification of diverticulitis and diverticular disease. Therefore, it is not easy to compare different studies. The evidence for therapy with antibiotics, mesalamine, probiotics and fibers are initially discussed and secondly therapeutic recommendations are given for the various stages of diverticular disease.


Assuntos
Doença Diverticular do Colo/terapia , Diverticulose Cólica/terapia , Antibacterianos/uso terapêutico , Fibras na Dieta/administração & dosagem , Doença Diverticular do Colo/prevenção & controle , Diverticulose Cólica/prevenção & controle , Medicina Baseada em Evidências , Humanos , Mesalamina/uso terapêutico , Probióticos/uso terapêutico
14.
J Crohns Colitis ; 7(7): e263-70, 2013 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-23182164

RESUMO

BACKGROUND: Predictive factors for a mild course of Crohn's disease (CD) may have therapeutic consequences, but as yet have not been identified. AIMS: To identify baseline factors that predict mild CD and design a predictive scoring system. METHODS: A retrospective, multicenter study of newly diagnosed CD patients allocated to mild CD (no therapy, mesalazine only, or mesalazine with a single initial short course of low-dose prednisone) or moderate CD (all other patients including resected patients). RESULTS: 162 patients (median follow-up 43 months) were analyzed: 47 mild CD and 115 moderate CD. For mild CD versus moderate CD, mean age at first diagnosis was higher (41.1 versus 33.9 years, p=0.02), mean C-reactive protein (CRP) concentration was lower (1.6 versus 3.6 mg/L, p<0.01), and perianal lesions were less frequent (0% versus 10.4%, p=0.02). The combined incidence of complications (stenosis, any type of fistula, extraintestinal complications or fever) was 21.3% in mild CD versus 35.7% in moderate CD (p=0.07). A scoring system based on age, CRP, endoscopic severity (adapted Rutgeert's score), perianal lesions and combined incidence of complications was developed which can predict a mild prognosis at the initial diagnosis, giving patients the chance of simplified therapy and accelerated step-up in the event of treatment failure. CONCLUSIONS: Approximately a third of CD patients experience a mild disease course and require only basic therapy. A possible scoring system to predict mild CD which may avoid overtreatment and unnecessary risks for the patient and costs is suggested.


Assuntos
Doença de Crohn/complicações , Adulto , Anti-Inflamatórios não Esteroides/uso terapêutico , Distribuição de Qui-Quadrado , Doença de Crohn/tratamento farmacológico , Feminino , Humanos , Incidência , Masculino , Mesalamina/uso terapêutico , Valor Preditivo dos Testes , Prednisona/uso terapêutico , Prognóstico , Estudos Retrospectivos , Índice de Gravidade de Doença
15.
Aliment Pharmacol Ther ; 34(9): 1115-22, 2011 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-21923715

RESUMO

BACKGROUND: Different oral formulations of 'mesalazine (mesalamine)' may have different efficacy in distal ulcerative colitis. AIM: To evaluate the efficacy of mesalazine granules (Salofalk granules) vs. mesalazine tablets (Salofalk tablets) as induction therapy in patients with distinct extensions of ulcerative colitis. METHODS: A pooled analysis of 705 patients from four prospective, randomised, double-blind phase III trials was performed. The efficacy of 8 weeks' induction with 3 g/day mesalazine granules [3 g once daily (o.d.) or 1 g three times daily (t.d.s)] vs. 3 g/day mesalazine tablets (1 g t.d.s.) was compared in terms of clinical remission (CR: CAI ≤ 4) and endoscopic remission (ER: EI ≤ 3) (both according to Rachmilewitz) in subgroups with pancolitis, left-sided colitis, or proctosigmoiditis. RESULTS: Mesalazine granules were equipotent to mesalazine tablets in pancolitis regarding CR (72% vs. 71%, P = 0.909) and ER (58% vs. 49%, P = 0.338). In left-sided colitis, both mesalazine formulations were equipotent regarding CR (66% vs. 67%; P = 0.843) but mesalazine granules were superior regarding ER (56% vs. 37%; P = 0.025). In proctosigmoiditis, mesalazine granules were significantly more effective than mesalazine tablets regarding CR (78% vs. 55% P < 0.001) and ER (67% vs. 43% P < 0.001). Furthermore, o.d. application of mesalazine granules was more effective than t.d.s. dosing in left-sided colitis (CR 73% vs. 62%, P = 0.181; ER 71% vs. 48% P = 0.005) and proctosigmoiditis (CR 86% vs. 73%, P = 0.020; ER 75% vs. 61%, P = 0.021), but not in pancolitis. CONCLUSION: This pooled analysis supports the hypothesis that mesalazine granules are superior to mesalazine tablets in induction of remission in distal colitis and should be taken once daily.


Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Colite Ulcerativa/tratamento farmacológico , Mesalamina/uso terapêutico , Ácidos Polimetacrílicos/uso terapêutico , Comprimidos com Revestimento Entérico/uso terapêutico , Administração Oral , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pós/administração & dosagem , Ensaios Clínicos Controlados Aleatórios como Assunto , Indução de Remissão , Índice de Gravidade de Doença , Estatística como Assunto , Resultado do Tratamento
16.
Internist (Berl) ; 49(12): 1415-6, 1418-20, 2008 Dec.
Artigo em Alemão | MEDLINE | ID: mdl-18946642

RESUMO

New concepts are developed in the therapy of diverticular disease. 5-aminosalicylates can be administered in patients with slight forms of diverticulitis. In moderate diverticulitis antibiotics should be applied alternatively or additionally. In cases of severe diverticulitis patients should be kept fasting with parenteral nutrition and intravenous broad spectrum antibiotics. Small abscesses can be treated conservatively while abscesses larger than 4 cm should be drained in a first step and than treated surgically. A free perforation is still an absolute indication for emergency operation. In recurring diverticulitis indication for resection of the affected segment of the bowel should be considered depending on the extent of former attacks.


Assuntos
Doença Diverticular do Colo/terapia , Abscesso/etiologia , Abscesso/terapia , Adulto , Idoso , Idoso de 80 Anos ou mais , Antibacterianos/uso terapêutico , Anti-Inflamatórios não Esteroides/uso terapêutico , Colonoscopia , Terapia Combinada , Estudos Transversais , Doença Diverticular do Colo/complicações , Doença Diverticular do Colo/diagnóstico , Doença Diverticular do Colo/epidemiologia , Hemorragia Gastrointestinal/etiologia , Hemorragia Gastrointestinal/terapia , Humanos , Perfuração Intestinal/etiologia , Perfuração Intestinal/terapia , Mesalamina/uso terapêutico , Pessoa de Meia-Idade , Equipe de Assistência ao Paciente , Recidiva , Encaminhamento e Consulta
17.
Gut ; 55(9): 1296-305, 2006 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-16492715

RESUMO

BACKGROUND AND AIMS: Portal hypertension in cirrhosis is mediated in part by increased intrahepatic resistance, reflecting an increased sensitivity of the hepatic microvasculature to vasoconstrictors. Activation of the RhoA/Rho-kinase pathway is essential for contraction of vascular smooth muscle. The aim of this study was to investigate RhoA/Rho-kinase mediated regulation of the intrahepatic vascular tone in cirrhotic rats. METHODS: Cirrhosis was induced by bile duct ligation (BDL). Hepatic RhoA and Rho-kinase expressions were studied by real time reverse transcription polymerase chain reaction and western blot analysis. Hepatic Rho-kinase activity in rat and human livers was assessed as phosphorylation of the Rho-kinase substrate moesin. The effect of the Rho-kinase inhibitor Y-27632 on hepatic perfusion pressure was measured in livers perfused at constant flow. The in vivo effect of intravenous application of Y-27632 was studied by haemodynamic measurements. RESULTS: Hepatic expressions of RhoA and Rho-kinase were increased at mRNA and protein level in BDL rats. Intrahepatic moesin phosphorylation was increased in livers from cirrhotic rats and patients with alcohol induced cirrhosis. Y-27632 reduced the basal perfusion pressure of in situ perfused livers in BDL rats but not in sham operated rats. Y-27632 reduced the sensitivity to methoxamine in isolated perfused livers in sham operated rats more than in BDL rats. In vivo, Y-27632 reduced portal pressure to a greater extent in BDL rats than in sham operated rats. Intrahepatic vascular resistance was decreased in response to bolus injection of Y-27632 in BDL rats but not in sham operated rats. CONCLUSIONS: Upregulation of RhoA and Rho-kinase contributes to increased intrahepatic resistance in cirrhotic rats and to an increased sensitivity of cirrhotic livers to vasoconstrictors.


Assuntos
Circulação Hepática , Cirrose Hepática Biliar/metabolismo , Proteínas Serina-Treonina Quinases/biossíntese , Proteína rhoA de Ligação ao GTP/biossíntese , Animais , Relação Dose-Resposta a Droga , Hemodinâmica/efeitos dos fármacos , Hipertensão Portal/etiologia , Hipertensão Portal/fisiopatologia , Peptídeos e Proteínas de Sinalização Intracelular , Fígado/metabolismo , Cirrose Hepática Biliar/complicações , Cirrose Hepática Biliar/fisiopatologia , Masculino , Metoxamina/farmacologia , Proteínas dos Microfilamentos/metabolismo , Fosforilação , Proteínas Serina-Treonina Quinases/antagonistas & inibidores , Proteínas Serina-Treonina Quinases/genética , Ratos , Ratos Sprague-Dawley , Reação em Cadeia da Polimerase Via Transcriptase Reversa/métodos , Transdução de Sinais , Regulação para Cima , Resistência Vascular , Vasoconstritores/farmacologia , Quinases Associadas a rho , Proteína rhoA de Ligação ao GTP/genética
18.
J Viral Hepat ; 13(4): 256-63, 2006 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-16611192

RESUMO

Acute hepatitis B progresses to liver failure with the need of liver transplantation in about 1% of cases. We treated patients with severe acute or fulminant hepatitis B with lamivudine in an attempt to prevent hepatitis B virus (HBV) reinfection after potential liver transplantation. Since September 2000, 17 patients with severe acute or fulminant HBV infection were treated with 100 or 150 mg lamivudine daily once we had evidence for a severe course as indicated by an INR >2.0. These were compared to a historic control from our unit and to external patients. Fourteen of the 17 patients (82.4%) survived with full recovery without liver transplantation. All these 14 individuals cleared HBsAg on lamivudine within less than 6 months. Twelve patients recovered quickly as indicated by a normalized prothrombin time within 1 week while two patients had a more prolonged course. None of the patients showed an adverse event. Three patients requiring transplantation despite lamivudine therapy had more advanced disease on admission, of whom one had additionally ingested paracetamol (acetaminophen) while the second was already HBV-DNA negative by polymerase chain reaction on admission. The lamivudine treated patients had significant higher frequency of survival without liver transplantation 82.4 vs 20% (4/20) in the historic control (P < 0.001). Similar data were derived from external centres using lamivudine (15/20, 75%). Lamivudine is safe in patients with severe acute or fulminant hepatitis B, leading to fast recovery with the potential to prevent liver failure and liver transplantation when administered early enough.


Assuntos
Antivirais/uso terapêutico , Vírus da Hepatite B/crescimento & desenvolvimento , Hepatite B/tratamento farmacológico , Lamivudina/uso terapêutico , Falência Hepática Aguda/tratamento farmacológico , Adulto , Alanina Transaminase/sangue , Antivirais/efeitos adversos , Aspartato Aminotransferases/sangue , Bilirrubina/sangue , DNA Viral/sangue , Feminino , Hepatite B/sangue , Hepatite B/virologia , Humanos , Lamivudina/efeitos adversos , Falência Hepática Aguda/sangue , Falência Hepática Aguda/virologia , Masculino , Pessoa de Meia-Idade , Tempo de Protrombina
19.
Aktuelle Radiol ; 7(5): 249-52, 1997 Sep.
Artigo em Alemão | MEDLINE | ID: mdl-9409997

RESUMO

We report the diagnosis and differential diagnosis of a hepatic pseudolesion due to percutaneous liver biopsy in a 30-year-old female patient with known chronic hepatitis C and renal insufficiency. In the course of transplant preparation, an abdominal spiral-CT examination pre and post i.v.-contrast injection as well as an angiography with CT-hepaticography and CT-portography were performed. In these examinations a 1 cm, hepatocellular-carcinoma mimicking liver lesion was found; it was hypodense in the CT-portography and showed a marked enhancement in the CT-hepaticography. This "pseudolesion", which was supposed to be due to the liver biopsy, resolved spontaneously.


Assuntos
Biópsia por Agulha , Hepatite C Crônica/patologia , Fígado/lesões , Tomografia Computadorizada por Raios X , Adulto , Angiografia , Artefatos , Carcinoma Hepatocelular/patologia , Diagnóstico Diferencial , Feminino , Humanos , Fígado/patologia , Neoplasias Hepáticas/patologia
20.
J Infect Dis ; 180(5): 1704-8, 1999 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-10515837

RESUMO

The intrahepatic expression of interleukin (IL)-1beta and tumor necrosis factor (TNF)-alpha was studied in liver specimens from patients with chronic hepatitis C (n=29) and primary biliary cirrhosis (PBC; n=12) and from normal controls (n=19). IL-1beta and TNF-alpha immunoreactivity was predominantly localized in sinusoidal cells, with IL-1beta immunoreactivity being weaker in chronic hepatitis C samples than in PBC or control samples, whereas no difference in staining intensity could be observed for TNF-alpha. On semiquantitation by reverse transcription/competitive polymerase chain reaction, IL-1beta mRNA levels were significantly lower in chronic hepatitis C than in PBC or control samples (chronic hepatitis C, 0.87+/-0.77; PBC, 7.96+/-3.32; control, 3.78+/-2.56 amole IL-1beta mRNA/fmole beta-actin mRNA; P<.001). In contrast, no significant differences in TNF-alpha mRNA levels were observed between the groups. The data suggest insufficient IL-1beta production by sinusoidal cells in chronic hepatitis C, which might facilitate viral persistence.


Assuntos
Hepatite C Crônica/imunologia , Interleucina-1/biossíntese , Fígado/imunologia , Fator de Necrose Tumoral alfa/biossíntese , Humanos , Imuno-Histoquímica , Interleucina-1/genética , Cirrose Hepática Biliar/imunologia , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Fator de Necrose Tumoral alfa/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA